Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

August 17, 2020August 17, 2020

Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer

News

The Australian Therapeutic Goods Administration (TGA) has approved Seattle Genetics’ Tukysa (tucatinib), when given alongside trastuzumab and Xeloda (capecitabine), for the treatment of patients with advanced inoperable or metastatic HER2-positive breast cancer, who ... Read more

August 10, 2020August 27, 2020

FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC

News

The U.S. Food and Drug Administration (FDA) has accepted to review two new Merck applications requesting the approval of Keytruda (pembrolizumab) for the treatment of patients with different forms ... Read more

July 23, 2020July 23, 2020

Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe

News

Devyser’s hereditary breast and ovarian cancer (HBOC) test has received a CE mark from the European Commission and is now approved as a diagnostic test for both cancers in Europe. The CE mark ... Read more

July 16, 2020July 16, 2020

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

News

Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying ... Read more

July 6, 2020July 6, 2020

Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery

News

When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 ... Read more

June 15, 2020June 15, 2020

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

News

An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or ... Read more

May 21, 2020May 21, 2020

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

News

Scientists have discovered a gene signature in certain types of breast cancer that can be used to determine the likelihood of these tumors responding to treatment with a new ... Read more

April 9, 2020April 9, 2020

Positive Results Support Early Halt to Phase 3 Trial Testing Sacituzumab Govitecan for TNBC

News

Immunomedics has halted its Phase 3 confirmatory trial of sacituzumab govitecan, due to strong evidence of its ability to delay disease progression in patients with advanced triple-negative breast cancer ... Read more

February 26, 2020February 26, 2020

New Formulation of Roche’s Perjeta-Herceptin Combo for HER2-Positive Breast Cancer Up for Possible FDA Approval

News

The U.S. Food and Drug Administration (FDA) will review Roche’s application seeking regulatory approval for a new formulation — given as a subcutaneous, or under-the-skin injection — of the ... Read more

January 2, 2020January 3, 2020

Enhertu Gets FDA Approval for Treatment of Advanced HER2-positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) approved Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received at least two ... Read more

Pin It on Pinterest